Form 4: MPM BioVentures Sells Shares in Entrada Therapeutics

MPM BioVentures 2018, L.P. and related entities sold a total of 44,722 shares of Entrada Therapeutics (TRDA) across two transactions on December 10th and 11th, 2024.

Summary

• MPM BioVentures 2018, L.P. and related entities, including MPM BioVentures 2014, L.P., sold shares of Entrada Therapeutics (TRDA) in two transactions.
• On December 10, 2024, 22,935 shares were sold at a weighted average price of $20.77 per share, with prices ranging from $20.356 to $21.315.
• On December 11, 2024, 21,787 shares were sold at a weighted average price of $20.23 per share, with prices ranging from $20.01 to $20.595.
• Following these transactions, MPM BioVentures 2018, L.P. and related entities beneficially own 4,381,062 shares of Entrada Therapeutics.

Sentiment

Score: 5

Explanation: The document is a routine regulatory filing detailing share sales, which is neither positive nor negative in itself.

Industry Context

This filing reflects routine trading activity by a major shareholder in a publicly traded company. Such transactions are common and are closely monitored by regulators and investors.

Comparison to Industry Standards

• Form 4 filings are standard practice for reporting changes in beneficial ownership by insiders in publicly traded companies.
• The share sales by MPM BioVentures are not unusual for venture capital firms that hold significant stakes in portfolio companies.
• The reported prices are within the typical trading range for the stock on the respective dates.

Stakeholder Impact

• The share sales may have a minor impact on the stock price of Entrada Therapeutics, but the overall impact is likely to be minimal given the relatively small volume of shares sold compared to the total outstanding shares.
• The transactions do not appear to have any significant impact on other stakeholders.

Key Dates

Keywords

Entrada Therapeutics, TRDA, MPM BioVentures, share sale, insider trading, equity securities